CN
Search Within
Y0000377
应用筛选条件
关键词:'Y0000377'
显示 1-30 共 196 条结果 关于 "Y0000377" 范围 论文
Xinran Liu et al.
The Journal of biological chemistry, 288(45), 32753-32765 (2013-10-03)
All viral RNA-dependent RNA polymerases (RdRps) have a conserved structural element termed motif D. Studies of the RdRp from poliovirus (PV) have shown that a conformational change of motif D leads to efficient and faithful nucleotide addition by bringing Lys-359
Jun Hou et al.
Journal of virology, 88(21), 12254-12264 (2014-08-08)
Systems biology has proven to be a powerful tool to identify reliable predictors of treatment response in chronic hepatitis C virus (HCV) infection. In the present study, we studied patients with chronic HCV infection who responded to interferon (IFN)-based therapy
Min Jiang et al.
Antimicrobial agents and chemotherapy, 58(9), 5456-5465 (2014-07-02)
VX-222, a thiophene-2-carboxylic acid derivative, is a selective nonnucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. In phase 1 and 2 clinical studies, VX-222 demonstrated effective antiviral efficacy, with substantial reductions in plasma HCV RNA in
F A Di Lello et al.
Archives of virology, 159(12), 3345-3351 (2014-08-28)
The aim of this study was to analyze the impact of core variations on sustained virological response (SVR) to pegylated interferon plus ribavirin (PEG-IFN/RBV) and its association with predictive factors of response in Caucasian patients infected with genotype 1 hepatitis
Akiyoshi Ogino et al.
Oncology letters, 8(6), 2469-2474 (2014-11-05)
Ribavirin (1-β-D-ribofuranosy-1,2,4-triazole-3-carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently
Erick De la Cruz-Hernandez et al.
Oncology reports, 33(5), 2384-2392 (2015-03-05)
The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5'-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2). A computational searching revealed that ribavirin has a high structural similarity
[Treatment of hepatitis C infection. A revolution should not hide another].
Philippe Sogni
Presse medicale (Paris, France : 1983), 43(4 Pt 1), 339-340 (2014-03-26)
A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C.
Chia-Yen Dai et al.
Hepatology (Baltimore, Md.), 60(6), 2128-2129 (2014-03-04)
Jordan J Feld et al.
The New England journal of medicine, 370(17), 1594-1603 (2014-04-12)
The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Mai T Pho et al.
Hepatology (Baltimore, Md.), 60(1), 12-14 (2014-05-16)
Tutik Sri Wahyuni et al.
Fitoterapia, 99, 276-283 (2014-12-03)
Hepatitis C virus (HCV) infection is highly prevalent among global populations, with an estimated number of infected patients being 170 million. Approximately 70-80% of patients acutely infected with HCV will progress to chronic liver disease, such as liver cirrhosis and
M Z Rahman et al.
Bangladesh Medical Research Council bulletin, 39(1), 11-13 (2013-08-08)
Peginterferon alpha-2a and ribavirin combination therapy achieves a sustained virological response (SVR) in patients with chronic hepatitis C. Little is know about long-term durability of hepatitis C virus--Ribonucleic acid (HCV-RNA) negativity in patient treated with pegylated interferon and ribavirin therapy.
Tamer Abdelrahman et al.
Hepatology (Baltimore, Md.), 61(1), 88-97 (2014-05-07)
High rates of sexually transmitted infection and reinfection with hepatitis C virus (HCV) have recently been reported in human immunodeficiency virus (HIV)-infected men who have sex with men and reinfection has also been described in monoinfected injecting drug users. The
Xiaochun Xie et al.
Archives of virology, 159(10), 2641-2650 (2014-06-04)
Previous studies have shown that RNA viruses can be attenuated by either increased or decreased viral polymerase replication fidelity. Although foot-and-mouth disease virus (FMDV) high-fidelity RNA-dependent RNA polymerase (RdRp) variants with an attenuated phenotype have been isolated using mutagens, no
Bruno Cacopardo et al.
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive, 21(1), 40-44 (2013-03-26)
Sarcoidosis is a chronic inflammatory multisystem disease of unknown aetiology. IFN-alfa is an immunomodulatory cytokine, currently used with ribavirin in the treatment of chronic hepatitis C infection. Due to its effects on the immune system, IFN-? may lead to the
Roy F Chemaly et al.
Journal of pediatric hematology/oncology, 36(6), e376-e381 (2013-12-12)
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections (LRTIs) in children, especially those with cancer. Data on RSV infections in this vulnerable population is limited. We conducted a retrospective study of all RSV infections in
Leah C Jimmerson et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 978-979, 163-172 (2015-01-03)
Ribavirin (RBV) is a nucleoside analog used to treat a variety of DNA and RNA viruses. RBV undergoes intracellular phosphorylation to a mono- (MP), di- (DP), and triphosphate (TP). The phosphorylated forms have been associated with the mechanisms of antiviral
Dennis J Hartigan-O'Connor et al.
The Journal of infectious diseases, 209(10), 1602-1612 (2013-12-12)
Interferon α (IFN-α) and ribavirin can induce a sustained virologic response (SVR) in some but not all hepatitis C virus (HCV)-infected patients. The mechanism of effective treatment is unclear. One possibility is that IFN-α differentially improves the functional capacity of
Jun-Ying Liu et al.
Virology journal, 9, 186-186 (2012-09-07)
Clinical and laboratory studies have indicated that coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) can suppress one another, eliciting a dominant disease phenotype. To assess whether HBV can influence the antiviral effect of treatment on HCV
Jianxiong Zeng et al.
Journal of virology, 88(8), 4008-4020 (2014-01-24)
Mutagenic nucleoside analogues can be used to isolate RNA virus high-fidelity RNA-dependent RNA polymerase (RdRp) variants, the majority of which are attenuated in vivo. However, attenuated foot-and-mouth disease virus (FMDV) high-fidelity RdRp variants have not been isolated, and the correlations
Giuseppe Bruno et al.
The new microbiologica, 38(1), 21-27 (2015-03-06)
Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 near the interleukin 28B gene are predictors of virological response (SVR) to IFN-based therapy for monoinfected chronic hepatitis C patients. We retrospectively evaluated the impact of IL28B SNPs and other factors on SVR
Paul Y Kwo et al.
The New England journal of medicine, 371(25), 2375-2382 (2014-11-12)
Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon-containing regimens are associated with low response rates owing to treatment-limiting toxic effects in immunosuppressed liver-transplant recipients. We evaluated the interferon-free regimen of the NS5A inhibitor
Lorenzo Rossaro et al.
Digestive diseases and sciences, 58(12), 3620-3625 (2013-10-25)
Patients in rural communities are less likely to receive treatment for their hepatitis C (HCV) infection. Telemedicine (TM) consultation can close the gap of access to specialists in remote and under-served areas. To determine treatment response and side-effect profiles among
D Teodor et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 116(4), 1039-1043 (2013-05-25)
Standard therapy in chronic hepatitis C virus infection is still a combination of peginterferon alfa2a/2b and ribavirin for 48 weeks. As of side effects, there are organic side effects, such as hematologic disorders, and functional side effects, reflected in the
Guido Stirnimann
Expert opinion on pharmacotherapy, 15(17), 2609-2622 (2014-10-28)
Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in
Michael Manns et al.
Lancet (London, England), 384(9941), 414-426 (2014-06-08)
Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained virological response can be suboptimum in patients with HCV genotype 1 infection. The efficacy
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
K Rajender Reddy et al.
Transplantation, 97(8), e47-e48 (2014-04-16)
Liwei An et al.
Antiviral research, 109, 54-63 (2014-06-28)
Infection with influenza A virus is still a global concern since it causes significant mortality, morbidity and economic loss. New burst pandemics and rapid emergence of drug-resistance strains in recent years call for novel antiviral therapies. One promising way to
Shaimuna Fareeha Sajjad et al.
JPMA. The Journal of the Pakistan Medical Association, 62(11), 1229-1232 (2013-07-23)
Recommended treatment of chronic Hepatitis C virus (HCV) infection is interferon and ribavirin. Most patients develop side effects during treatment. Weight loss is one of the side effects of interferon therapy. Present study was conducted at Pakistan Medical and Research
Susanne Sarkar et al.
The British journal of psychiatry : the journal of mental science, 206(1), 45-51 (2014-11-02)
Antiviral therapy with interferon-alpha (IFN-α) for hepatitis C virus (HCV) infection is associated with increased risk for depression. To identify clinical predictors for IFN-α-induced depression during antiviral therapy for HCV infection. Depression (defined with the Montgomery-Åsberg Depression Rating Scale (MADRS))
1/7